Breakthrough biomarker predicts recurrence risk in clear cell renal cancer

Michigan Medicine - University of MichiganJun 25 2024 Kidney cancer accounts for about 3-5% of all cancers; clear cell renal cancer makes up about 75% of all kinds of kidney cancers. Currently, treatment for clear cell renal cancer is determined based on the size and grade of the tumor and stage of overall disease. We need biomarkers to identify and better treat those who need to be treated and avoid treatment in those that that do not need to be treated.

For example, some patients with stage pT3 disease may never develop recurrence after initial treatment with surgery to remove the kidney. Rather than offer additional, often toxic, systemic therapy to all patients with pT3 disease, a biomarker test that can stratify patients into low versus high risk for recurrence can be used to guide need for additional therapy.

Related Stories"We've developed a 15-gene signature that can risk-stratify patients with clear cell renal cancer from low to high," said Salami. "Even when we adjusted for other clinical variables, like age or grade of tumor, this signature was still independently associated with recurrence after treatment for this form of kidney cancer."

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Researchers identify a novel biomarker linked to renal cancer recurrenceResearchers from the University of Michigan Health Rogel Cancer Center have discovered a biomarker that could help identify which renal cancer patients have a higher risk of recurrence.
Source: medical_xpress - 🏆 101. / 51 Read more »

Study sheds light on pediatric DIPG tumor mechanismsResearchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.
Source: NewsMedical - 🏆 19. / 71 Read more »

Study finds pediatric brain tumors rely on different metabolic 'route' to fuel treatment resistanceResearchers at the University of Michigan Health Rogel Cancer Center are one step closer to understanding how pediatric DIPG tumors work.
Source: medical_xpress - 🏆 101. / 51 Read more »